CD43 (MT1)

From 70 to 90% of T-cell Lymphomas and from 22 to 37% of B cell Lymphomas are labeled with this antibody. No reactivity has been observed with reactive B cells. So, a B lineage population that co-expresses a T-cell marker is highly likely to be a malignant lymphoma rather than a reactive B cell population. When used in combination with CD45 and L26, effective immunophenotyping of the majority of paraffin-embedded lymphomas can be obtained. Co-staining of a lymphoid infiltrate with CD20 and CD3 argues against a reactive process and favors lymphoma.